How much does branded tirzepatide (Zepbound, Mounjaro) cost?
Tirzepatide is sold under two brand names by Eli Lilly. Mounjaro is approved for type 2 diabetes management; Zepboundis approved for chronic weight management. They are the same molecule at the same doses — the approved indication and labeling differ.
At US retail pharmacy prices without insurance or manufacturer savings programs, both products typically fall in the range of $900–$1,100 per monthfor a four-week supply of the injection pens. This pricing reflects the manufacturer’s list price and is not fixed — it can change with manufacturer pricing decisions, formulary negotiations, or policy changes.
For most patients without insurance coverage, this price is a significant barrier to sustained use. That cost structure is a primary reason compounded alternatives have become relevant for many patients.
Does insurance cover tirzepatide?
Insurance coverage for tirzepatide is substantially more complex than it might appear from the manufacturer’s messaging.
Mounjaro (diabetes indication): Most commercial insurance plans cover Mounjaro for patients with a type 2 diabetes diagnosis, subject to prior authorization, step therapy requirements, and formulary tier placement. Out-of-pocket costs after coverage vary significantly by plan.
Zepbound (weight management indication): Coverage is much more variable. Many commercial insurance plans exclude anti-obesity medications specifically — a legacy of how these medications have historically been classified. Even plans that cover some weight-loss medications may require prior authorization, BMI thresholds, documentation of prior treatment attempts, or other criteria.
Medicare: As of current federal law, Medicare Part D does not cover anti-obesity medications used for weight management. Medicare coverage of Mounjaro is available if the patient has a type 2 diabetes diagnosis, but not for weight management alone.
Medicaid: Coverage varies by state. Some state Medicaid programs cover anti-obesity medications; many do not. Verify with your state program directly.
Before assuming your plan covers tirzepatide, call the member services number on your insurance card and ask specifically about Zepbound for weight management (not just “GLP-1 medications generally”), including any prior authorization requirements.
Manufacturer savings programs
Eli Lilly offers savings programs for both Mounjaro and Zepbound for eligible patients. These programs can substantially reduce out-of-pocket costs for commercially insured patients — in some cases bringing monthly cost to a fraction of the retail price.
Key limitations apply: savings programs are generally not available to patients on Medicare, Medicaid, or other federal healthcare programs. Eligibility criteria apply. Program terms can change. They are useful for eligible patients but are not a universal solution.
Branded tirzepatide runs roughly $900 to $1,100 a month without insurance; compounded tirzepatide through a 503A telehealth program commonly runs $150 to $400.
Why is compounded tirzepatide cheaper, and how does its pricing work?
Compounded tirzepatide is prepared by licensed 503A compounding pharmacies in the United States using pharmaceutical-grade tirzepatide bulk substance. Compounded preparations are not FDA-approved; they are not the same product as branded Zepbound or Mounjaro. They are prescription medications compounded for an individual patient by a licensed pharmacist.
The cost of compounded tirzepatide through a telehealth program typically ranges from roughly $150 to $400 per month, though this varies meaningfully by dose, pharmacy, and program structure. Lower-dose starting tiers tend to cost less; higher maintenance doses cost more.
Why is compounded tirzepatide cheaper? The manufacturer’s pricing reflects R&D investment, FDA approval costs, branded marketing, and distribution margins. Compounded preparations bypass those layers because they are not manufactured products — they are individually prepared prescriptions. The pharmacy’s cost is primarily the bulk ingredient and compounding labor.
Programs that offer compounded tirzepatide at prices well below this range often signal a problem — either the medication is sourced from outside the United States (which is neither legal nor safe), or the clinical component is a formality rather than a real evaluation.
What does a complete tirzepatide program cost include?
Evaluating the true monthly cost of a tirzepatide program requires looking at the full picture, not just the medication price. Components that may be priced separately or bundled include:
- Initial clinical evaluation— some programs charge a one-time consultation fee; others build it into the subscription. Ask explicitly.
- The medication itself— the compounded tirzepatide, per month.
- Supplies— syringes, needles, alcohol swabs. Some programs include these; others do not.
- Ongoing clinician check-ins— follow-up visits for dose management, response assessment, and side-effect management. These matter and should be included or clearly priced.
- Lab work— initial labs and follow-up labs are a clinical best practice. Some programs coordinate this; most do not include the cost of labs.
What is the cost of not treating effectively?
Obesity-related comorbidities — type 2 diabetes, hypertension, sleep apnea, dyslipidemia, osteoarthritis — carry both direct healthcare costs and indirect quality-of-life costs. For patients with significant metabolic risk, the health-economic calculus includes what the medications cost versus what the long-term condition management costs.
The SURMOUNT-1 trial, which enrolled adults with obesity without type 2 diabetes, found that tirzepatide at the highest dose produced mean weight reduction of approximately 22.5% over 72 weeks. That magnitude of weight loss, for patients at elevated cardiovascular or metabolic risk, can materially change their clinical risk trajectory.
This is not an argument to prescribe tirzepatide for every patient who asks. It is context for understanding why the monthly cost, while real, is not the only financial variable in the equation. A clinician who evaluates you for this medication will help you think through the full picture.